Staidson Biopharmaceuticals Hits Day High with Strong 3.02% Intraday Surge

Staidson (Beijing) Biopharmaceuticals Co., Ltd. has experienced a notable increase of 3.02% on July 20, 2026, reaching an intraday high of CNY 25.93. This performance stands in contrast to the China Shanghai Composite, which gained only 0.85% on the same day. Over the past week, Staidson has shown a robust performance with a 7.63% increase, while the broader market has declined by 3.0%. In the longer term, Staidson's performance over the past month has been particularly strong, with a 23.12% rise compared to the China Shanghai Composite's decline of 7.19%. However, the company has faced significant challenges over the past year, with a decline of 45.39%, while the market has seen a positive return of 7.41%. Staidson operates within the Pharmaceuticals & Biotechnology sector and holds a market capitalization of CNY 11,063 million. Despite recent gains, the company has reported negative net sales and pre-tax profits, indicating ongoing financial difficulties. The stock's performance metrics suggest a complex landscape for investors as the company navigates its current challenges.